DB-2304

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameDB-2304
Drug Alias NameDB-2304
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionC-Type lectin domain family 4 member C modulators
TargetsC-Type lectin domain family 4 member C
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDuality Biologics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDuality Biologics (Suzhou) Co LtdDuality Biologics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A